Chemomab Therapeutics (CMMB) Investor presentation summary

Strategic merger and corporate overview

• Scipher Medicine and Chemomab Therapeutics are merging in an all-stock transaction, with Scipher shareholders expected to own 68% and Chemomab shareholders 32% of the combined company.

• The combined entity will be named Scipher Medicine Corporation and listed on Nasdaq under the ticker SCIP.

• Chemomab shareholders will receive contingent value rights (CVRs), and the merger is expected to close before the end of 2026.

• Dr. Reg Seeto will serve as CEO, with Dr. Adi Mor joining the board.

• A $30M PIPE financing at a $150M pre-money valuation is expected to provide cash runway into mid-2028.

Rheumatoid arthritis (RA) market and unmet need

• RA represents a $24B+ global market with significant unmet need due to inadequate response rates and safety concerns with current therapies.

• Only one in three moderate-to-severe RA patients achieves low disease activity, and most therapies focus solely on inflammation.

• 72% of leading RA therapies carry black box safety warnings, highlighting the need for safer, more effective treatments.

• No novel phase 3 drugs are currently in US development for RA, leaving the market ripe for disruption.

Precision medicine and platform capabilities

• Scipher's Spectra AI Network Medicine platform identifies novel therapeutic targets and supports patient stratification.

• The platform mapped over 95% of human protein-protein interactions and ranks targets based on network disruption and phenotype reversal.

• PrismRA is the first CMS-approved molecular signature test for RA treatment response, with ~50,000 tests ordered by 1,700 rheumatologists.

• Real-world data show PrismRA significantly improves patient outcomes and changes prescribing behavior, reducing TNFi use and increasing alternative therapies.